Traveler reviewing travel insurance options for Schengen Visa - Global Banking & Finance Review
An image depicting a traveler exploring last-minute Schengen travel insurance options, emphasizing its importance for obtaining a visa and ensuring coverage before flying. This relates to the article's focus on travel insurance requirements for Europe.
Top Stories

INNOVATIVE BIOSCIENCE COMPANY CELL GUIDANCE SYSTEMS RAISES £243K ON CROWDCUBE INVESTMENT TARGET BEATEN BY ALMOST 150%

Published by Gbaf News

Posted on October 28, 2013

4 min read

· Last updated: October 29, 2013

Add as preferred source on Google

Capital will finance CGS’s growth in the dynamic stem cell research sector

Equity Crowdfunding Campaign Success

Cambridge based Cell Guidance Systems, which provides products and services for stem cell scientists, has successfully raised £242,800 on the equity crowdfunding platform Crowdcube exceeding its investment target by a massive 142 per cent.  Crowdcube has now helped over 70 British businesses to raise a more than £14.5 million.

Dr Michael Jones Innovative bioscience company

Dr Michael Jones Innovative bioscience company

Shareholder Growth and Company Background

A total of 139 people are new shareholders in Cell Guidance Systems, owning a share of 12.14 per cent of the equity in the business. Founded in 2010, the company makes cutting-edge research tools that simplify and accelerate the activities of scientists developing stem cell treatments and undertaking medical research. Its products and services improve methods for tasks such as exosome purification, which are traditionally very time consuming, inefficient and expensive. The company has 200 customers in more than 20 countries.

Future Plans and Investment Utilization

Cell Guidance Systems will use the investment to support its next stages of growth through increasing marketing, product development and product licensing activities and recruiting additional R&D staff.

Cell Guidance System’s founder, Dr Michael Jones, says: “Reaching our fundraising target will allow us to focus on our longterm goals of building our R&D capabilities, IP and product portfolio as well as our reach to the market. Setting up the pitch took quite a lot of effort, but we received full support from Crowdcube and the response from Crowdcube investors was amazing. I’m happy that we chose this funding route.”

Luke Lang, co-founder of Crowdcube, comments: “Cell Guidance System is targeting a fast-growing sector, and we’re excited by the success of its pitch on Crowdcube, which will allow it to take full advantage of the opportunity. Biosciences and stem cell research are a very complex industry and the successful funding clearly demonstrates Crowdcube investors’ growing sophistication and a real appetite for investing in innovative home-grown companies.”

Enterprise Investment Scheme Benefits

Those investing in Cell Guidance Systems are eligible for the Enterprise Investment Scheme (EIS), which offers income tax relief of up to 30 per cent on the amount invested and no capital gains tax on disposal.

Capital will finance CGS’s growth in the dynamic stem cell research sector

Cambridge based Cell Guidance Systems, which provides products and services for stem cell scientists, has successfully raised £242,800 on the equity crowdfunding platform Crowdcube exceeding its investment target by a massive 142 per cent.  Crowdcube has now helped over 70 British businesses to raise a more than £14.5 million.

Dr Michael Jones Innovative bioscience company

Dr Michael Jones Innovative bioscience company

A total of 139 people are new shareholders in Cell Guidance Systems, owning a share of 12.14 per cent of the equity in the business. Founded in 2010, the company makes cutting-edge research tools that simplify and accelerate the activities of scientists developing stem cell treatments and undertaking medical research. Its products and services improve methods for tasks such as exosome purification, which are traditionally very time consuming, inefficient and expensive. The company has 200 customers in more than 20 countries.

Cell Guidance Systems will use the investment to support its next stages of growth through increasing marketing, product development and product licensing activities and recruiting additional R&D staff.

Cell Guidance System’s founder, Dr Michael Jones, says: “Reaching our fundraising target will allow us to focus on our longterm goals of building our R&D capabilities, IP and product portfolio as well as our reach to the market. Setting up the pitch took quite a lot of effort, but we received full support from Crowdcube and the response from Crowdcube investors was amazing. I’m happy that we chose this funding route.”

Luke Lang, co-founder of Crowdcube, comments: “Cell Guidance System is targeting a fast-growing sector, and we’re excited by the success of its pitch on Crowdcube, which will allow it to take full advantage of the opportunity. Biosciences and stem cell research are a very complex industry and the successful funding clearly demonstrates Crowdcube investors’ growing sophistication and a real appetite for investing in innovative home-grown companies.”

Those investing in Cell Guidance Systems are eligible for the Enterprise Investment Scheme (EIS), which offers income tax relief of up to 30 per cent on the amount invested and no capital gains tax on disposal.

Key Takeaways

  • Cell Guidance Systems (CGS) raised £242,800 via Crowdcube, surpassing its target by approximately 142%.
  • The crowdfund brought in 139 new shareholders and sold 12.14% equity in the company.
  • Founded in 2010 and based in Cambridge, CGS provides tools for stem cell scientists, serving around 200 customers in 20+ countries.
  • Funds will support marketing, product development, licensing, and hiring R&D staff; investments are EIS‑eligible, offering UK tax incentives.

References

Frequently Asked Questions

What company raised the crowdfunding?
Cell Guidance Systems, a Cambridge‑based stem cell research tools provider.
How much was raised and by how much did it exceed the goal?
£242,800 was raised, exceeding its target by about 142%.
How many new shareholders participated?
139 new shareholders participated in the round.
What will the funds be used for?
Marketing, product development and licensing, and recruitment of additional R&D staff.
Are there tax benefits for investors?
Yes, investments are eligible for the UK Enterprise Investment Scheme (EIS) with up to 30% income tax relief and capital gains tax exemption.

Tags

Related Articles

More from Top Stories

Explore more articles in the Top Stories category